drugset / Trial / NCT02174900

Safety of Primaquine + Artemether-lumefantrine in G6PD Deficient Males With an Asymptomatic Malaria Infection (SAFEPRIM)

NCT02174900

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the tolerability and safety of increasing doses of primaquine in combination with artemether-lumefantrine in G6PD deficient males with an asymptomatic P. falciparum malaria infection.

Timeline

Start
2014-10
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Primaquine Small molecule 0.25 mg/kg
Subject Primaquine Small molecule 0.4 mg/kg
Comparator Artemether-lumefantrine Unknown